The time and background of Daprodustat’s launch in Japan

Daprodustat (Daprodustat) is a novel oral hemoglobin-stimulating agent (HIF-PHI) used to treat anemia associated with chronic kidney disease. Different from traditional erythropoietin (ESA) injection treatment, daprostat improves anemia symptoms by activating the synthesis of endogenous erythropoietin, and is administered orally, which is more convenient. In Japan, the treatment of anemia in chronic kidney disease has long relied on ESA drugs. Patients have low compliance with treatment, and side effects such as high blood pressure may occur during treatment.

Japan is a country with more chronic kidney disease patients in the world, especially a higher proportion of dialysis patients. Patients with chronic kidney disease generally require long-term anemia treatment, and traditional ESA injection drugs have problems such as poor patient compliance and higher cardiovascular risks. Daprostat, an oral drug, provides patients with a new treatment option by promoting the production of endogenous erythropoietin. In addition, daprostat has unique advantages in the regulation of iron metabolism and erythropoiesis, helping to reduce dependence on blood transfusions.

Daprostat was approved by the Japanese Ministry of Health, Labor and Welfare in June 2020 and was officially launched. The launch of this drug marks a major progress in the treatment of anemia in chronic kidney disease in Japan. Since the Japanese market has a high demand for the treatment of anemia related to chronic kidney disease, the launch of daprostat provides patients with a more convenient and safer treatment option.

The launch of dapostat in Japan not only provides patients with the convenience of oral treatment, but also promotes innovation in the treatment of anemia in chronic kidney disease. As the drug becomes more popular, patients' treatment outcomes and quality of life are expected to improve significantly.

In summary, dapostat was launched in Japan in June 2020, providing a new treatment option for the treatment of chronic kidney disease-related anemia and bringing hope to chronic kidney disease patients around the world.

Reference materials:https://en.wikipedia.org/wiki/Daprodustat